Russell Investments Group
VRDN icon

Russell Investments Group’s Viridian Therapeutics VRDN Stock Holding History

Russell Investments Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Sell
115,296
-119,255
-51% -$1.92M ﹤0.01% 2062
2026
Q1 		$4.59M Buy
234,551
+41,072
+21% +$1.22M ﹤0.01% 1401
2025
Q4 		$6.02M Buy
193,479
+58,482
+43% +$1.6M 0.01% 1201
2025
Q3 		$2.91M Buy
134,997
+47,112
+54% +$850K ﹤0.01% 1647
2025
Q2 		$1.23M Sell
87,885
-110,373
-56% -$1.5M ﹤0.01% 1962
2025
Q1 		$2.67M Sell
198,258
-181,338
-48% -$3.09M ﹤0.01% 1534
2024
Q4 		$7.28M Sell
379,596
-62,738
-14% -$1.36M 0.01% 973
2024
Q3 		$10.1M Buy
442,334
+92,703
+27% +$1.52M 0.01% 835
2024
Q2 		$4.55M Buy
349,631
+28,025
+9% +$388K 0.01% 1195
2024
Q1 		$5.63M Sell
321,606
-7,878
-2% -$153K 0.01% 1113
2023
Q4 		$7.18M Buy
329,484
+30,343
+10% +$479K 0.01% 960
2023
Q3 		$4.59M Buy
299,141
+195,616
+189% +$3.73M 0.01% 1124
2023
Q2 		$2.46M Buy
103,525
+18,790
+22% +$482K ﹤0.01% 1452
2023
Q1 		$2.16M Sell
84,735
-392
-0.5% -$12.6K ﹤0.01% 1538
2022
Q4 		$2.49M Buy
85,127
+40,328
+90% +$929K 0.01% 1455
2022
Q3 		$917K Buy
+44,799
New +$805K ﹤0.01% 1976
2017
Q4 		– Sell
-1,072
Closed -$147K – 3013
2017
Q3 		$147K Buy
+1,072
New +$180K ﹤0.01% 2720

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Russell Investments Group's VRDN Position: Q2 2026 in Review

Russell Investments Group reduced its Viridian Therapeutics (VRDN) stake by 51% in Q2 2026, selling an estimated $1.92M and leaving 115,296 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

Russell Investments Group first reported a position in VRDN in Q3 2017 and has held it in 17 quarters since. The position peaked at $10.1M in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Russell Investments Group held 115,296 shares of Viridian Therapeutics worth $2.12M as of Q2 2026.
  • Russell Investments Group sold 119,255 Viridian Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Viridian Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2062 holding.
  • Russell Investments Group first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 17 quarters since.
  • Russell Investments Group's Viridian Therapeutics position peaked at $10.1M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.